saolrx.comCrawled Nov 14, 2026
ROSWELL, Ga. and DUBLIN and HAMILTON, Bermuda, May 3, 2022 /PRNewswire/ -- Saol Therapeutics, a privately held, clinical-stage pharmaceutical company, announced today that the first patient has been enrolled in the company's Phase II RAISE Spasticity Trial.
Saol Therapeutics completed enrollment for its Phase 3 trial of Sodium Dichloroacetate (DCA) to treat Pyruvate Dehydrogenase Complex Deficiency (PDCD), a rare pediatric mitochondrial disease.
FDA grants a Type A meeting on December 18th to review new and expanded datasets submitted by Saol to help identify a feasible path forward without the need for an additional clinical trial
Financing will fund launch readiness for SL1009 and support lifecycle expansion into Congenital Lactic Acidosis and additional pain indications for SL1002
Saol Therapeutics acquired three hyperimmune products—WinRho SDF, HepaGam B, and VARIZIG—from Aptevo Therapeutics.
Saol Therapeutics received FDA approval for LYVISPAH (baclofen) oral granules and sold its plasma-derived hyperimmune portfolio to Kamada Ltd. for up to $160 million.
Saol Therapeutics reported progress in its clinical programs, including SL1009 for Pyruvate Dehydrogenase Complex Deficiency (PDCD) and SL1002 for osteoarthritis knee pain and spasticity.
Saol Therapeutics presented Phase III trial results for Sodium Dichloroacetate (DCA) in treating Pyruvate Dehydrogenase Complex Deficiency (PDCD).
The CDC updated its website to confirm VARIZIG’s availability through specialty distributors in the United States.
Saol Therapeutics seeks partnerships to improve patient care and company collaboration.
Learn About Saol Therapeutics. Founded in 2015 by a leadership group who firmly believes that better is always achievable.
Saol Therapeutics operates offices in the United States, Ireland, and Bermuda for general inquiries, business development, and funding requests.
Saol Therapeutics is a late-stage development company focused on advancing proprietary, novel therapies that address substantial unmet needs.